Sjogrens Disease
12
4
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.4% vs benchmark
8%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (12)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
OM336 in Seropositive Autoimmune Diseases
Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study
Tolerance and Efficacy of Rituximab in Sjogren's Disease
Quest to Analyze One Thousand Humans Meditating
A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome
Multi-Colored Placido Disk Viability
Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Cord Blood Serum in the Treatment of Ocular Surface Diseases